Chimeric Antigen Receptors Targeting Human Cytomegalovirus.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
04 08 2020
Historique:
received: 11 02 2020
accepted: 10 04 2020
pubmed: 15 4 2020
medline: 3 3 2021
entrez: 15 4 2020
Statut: ppublish

Résumé

Human cytomegalovirus (CMV) is a ubiquitous pathogen that causes significant morbidity in some vulnerable populations. Individualized adoptive transfer of ex vivo expanded CMV-specific CD8+ T cells has provided proof-of-concept that immunotherapy can be highly effective, but a chimeric antigen receptor (CAR) approach would provide a feasible method for broad application. We created 8 novel CARs using anti-CMV neutralizing antibody sequences, which were transduced via lentiviral vector into primary CD8+ T cells. All CARs were expressed. Activity against CMV-infected target cells was assessed by release of cytokines (interferon-γ and tumor necrosis factor-α), upregulation of surface CD107a, proliferation, cytolysis of infected cells, and suppression of viral replication. While some CARs showed varying functional activity across these assays, 1 CAR based on antibody 21E9 was consistently superior in all measures. These results support development of a CMV-specific CAR for therapeutic use against CMV and potentially other applications harnessing CMV-driven immunotherapies.

Identifiants

pubmed: 32285133
pii: 5819787
doi: 10.1093/infdis/jiaa171
pmc: PMC7399702
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Receptors, Chimeric Antigen 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

853-862

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI103960
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI128913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181045
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA033572
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI028697
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA111412
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

J Virol. 1996 Sep;70(9):5799-806
pubmed: 8709196
PLoS Pathog. 2014 Nov 20;10(11):e1004524
pubmed: 25412505
Hum Vaccin Immunother. 2012 Nov 1;8(11):1668-81
pubmed: 23151448
Bone Marrow Transplant. 1994;14 Suppl 4:S78-84
pubmed: 7728132
J Virol. 2016 Jul 11;90(15):6999-7006
pubmed: 27226366
Eur J Immunol. 2002 Jun;32(6):1659-69
pubmed: 12115649
Nature. 1996 Oct 24;383(6602):720-2
pubmed: 8878482
Blood. 2004 May 1;103(9):3565-72
pubmed: 14670917
Gene Ther. 2008 Nov;15(21):1411-23
pubmed: 18496571
Infect Drug Resist. 2019 Jun 04;12:1481-1491
pubmed: 31239725
AIDS. 2010 Nov 13;24(17):2619-28
pubmed: 20881472
J Virol. 2004 Sep;78(18):10023-33
pubmed: 15331735
Med Microbiol Immunol. 2015 Jun;204(3):285-93
pubmed: 25732096
N Engl J Med. 1995 Oct 19;333(16):1038-44
pubmed: 7675046
Mol Immunol. 2007 Feb;44(5):680-90
pubmed: 16824601
Front Microbiol. 2016 Jun 09;7:844
pubmed: 27375569
Int J Biol Macromol. 1995 Feb;17(1):37-42
pubmed: 7772562
J Virol. 2012 Sep;86(18):9854-65
pubmed: 22761372
Hum Gene Ther. 2004 Oct;15(10):976-88
pubmed: 15585113
Mol Immunol. 1994 Sep;31(13):983-91
pubmed: 7521934
J Virol. 2007 May;81(10):4973-80
pubmed: 17329324
J Virol. 2010 Apr;84(8):4083-8
pubmed: 20147393
Transplant Proc. 2018 Dec;50(10):3756-3762
pubmed: 30586840
Virology. 2003 Jan 5;305(1):201-9
pubmed: 12504553
Clin Infect Dis. 2006 Nov 1;43(9):1143-51
pubmed: 17029132
J Virol Methods. 1989 Feb;23(2):157-67
pubmed: 2542350
J Exp Med. 2005 Sep 5;202(5):673-85
pubmed: 16147978
J Virol Methods. 2003 Jun 30;110(2):137-42
pubmed: 12798240
Clin Cancer Res. 2015 Jul 1;21(13):2993-3002
pubmed: 25838392
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8
pubmed: 16319222
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14976-81
pubmed: 14657367
Science. 1992 Jul 10;257(5067):238-41
pubmed: 1352912
J Clin Invest. 1988 May;81(5):1511-8
pubmed: 2452836
Curr Protoc Microbiol. 2010 Aug;Chapter 14:Unit 14E.3
pubmed: 20812216
J Virol. 2015 Dec;89(23):11884-98
pubmed: 26378171

Auteurs

Ayub Ali (A)

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Flavia Chiuppesi (F)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Minh Nguyen (M)

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Mary Ann Hausner (MA)

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.

Jenny Nguyen (J)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Mindy Kha (M)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Angelina Iniguez (A)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Felix Wussow (F)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Don J Diamond (DJ)

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.

Otto O Yang (OO)

Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
AIDS Healthcare Foundation, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH